MA51828B1 - Macrocycles utilisés en tant que modulateurs du régulateur de la conductance transmembranaire de fibrose kystique, compositions pharmaceutiques de ceux-ci, leur utilisation dans le traitement de la fibrose kystique et procédé de fabrication associé - Google Patents
Macrocycles utilisés en tant que modulateurs du régulateur de la conductance transmembranaire de fibrose kystique, compositions pharmaceutiques de ceux-ci, leur utilisation dans le traitement de la fibrose kystique et procédé de fabrication associéInfo
- Publication number
- MA51828B1 MA51828B1 MA51828A MA51828A MA51828B1 MA 51828 B1 MA51828 B1 MA 51828B1 MA 51828 A MA51828 A MA 51828A MA 51828 A MA51828 A MA 51828A MA 51828 B1 MA51828 B1 MA 51828B1
- Authority
- MA
- Morocco
- Prior art keywords
- cystic fibrosis
- making
- pharmaceutical compositions
- modulators
- treatment
- Prior art date
Links
- 201000003883 Cystic fibrosis Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 title 1
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 title 1
- 150000002678 macrocyclic compounds Chemical class 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
L'invention concerne des composés de formule (i), des sels pharmaceutiquement acceptables de ceux-ci, des dérivés deutérés et des métabolites de l'un quelconque des précédents. L'invention concerne également des compositions pharmaceutiques les comprenant, des méthodes de traitement de la fibrose kystique à l'aide de celles-ci, et des procédés de fabrication de celles-ci.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862631453P | 2018-02-15 | 2018-02-15 | |
PCT/US2019/018042 WO2019161078A1 (fr) | 2018-02-15 | 2019-02-14 | Macrocycles utilisés en tant que modulateurs du régulateur de la conductance transmembranaire de fibrose kystique, compositions pharmaceutiques de ceux-ci, leur utilisation dans le traitement de la fibrose kystique et procédé de fabrication associé |
Publications (2)
Publication Number | Publication Date |
---|---|
MA51828A MA51828A (fr) | 2020-12-23 |
MA51828B1 true MA51828B1 (fr) | 2022-11-30 |
Family
ID=65529899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA51828A MA51828B1 (fr) | 2018-02-15 | 2019-02-14 | Macrocycles utilisés en tant que modulateurs du régulateur de la conductance transmembranaire de fibrose kystique, compositions pharmaceutiques de ceux-ci, leur utilisation dans le traitement de la fibrose kystique et procédé de fabrication associé |
Country Status (37)
Country | Link |
---|---|
US (2) | US11066417B2 (fr) |
EP (2) | EP3752510B1 (fr) |
JP (3) | JP7214743B2 (fr) |
KR (1) | KR102482271B1 (fr) |
CN (2) | CN112004817B (fr) |
AR (1) | AR114254A1 (fr) |
AU (2) | AU2019222758B2 (fr) |
BR (1) | BR112020015509A2 (fr) |
CA (1) | CA3088577A1 (fr) |
CL (1) | CL2020002055A1 (fr) |
CR (1) | CR20200403A (fr) |
DK (1) | DK3752510T3 (fr) |
DO (1) | DOP2023000016A (fr) |
EA (1) | EA202091930A1 (fr) |
EC (1) | ECSP20053845A (fr) |
ES (1) | ES2939775T3 (fr) |
FI (1) | FI3752510T3 (fr) |
GE (1) | GEP20237571B (fr) |
HR (1) | HRP20230030T1 (fr) |
HU (1) | HUE061046T2 (fr) |
IL (2) | IL294042A (fr) |
JO (1) | JOP20200178A1 (fr) |
LT (1) | LT3752510T (fr) |
MA (1) | MA51828B1 (fr) |
MD (1) | MD3752510T2 (fr) |
MX (1) | MX2020008268A (fr) |
PE (1) | PE20210454A1 (fr) |
PL (1) | PL3752510T3 (fr) |
PT (1) | PT3752510T (fr) |
RS (1) | RS64018B1 (fr) |
SG (1) | SG11202006614VA (fr) |
SI (1) | SI3752510T1 (fr) |
TW (2) | TWI828358B (fr) |
UA (1) | UA126304C2 (fr) |
UY (1) | UY38093A (fr) |
WO (1) | WO2019161078A1 (fr) |
ZA (1) | ZA202004357B (fr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2020008268A (es) | 2018-02-15 | 2020-09-21 | Vertex Pharma | Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quistica, composiciones farmaceuticas de estos, su uso en el tratamiento de la fibrosis quistica y procesos para elaborarlos. |
MA54227B1 (fr) | 2018-11-14 | 2023-03-31 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
CN114585628B (zh) * | 2019-08-14 | 2024-03-26 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节因子的调节剂 |
TW202120517A (zh) * | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
BR112022002605A2 (pt) * | 2019-08-14 | 2022-05-03 | Vertex Pharma | Formas cristalinas de moduladores de cftr |
CN110551077B (zh) * | 2019-09-24 | 2023-01-31 | 新乡市润宇新材料科技有限公司 | 一种光催化分子氧氧化制备n-叔丁基-2-苯并噻唑亚磺酰胺的方法 |
MX2022005810A (es) * | 2019-11-12 | 2022-06-08 | Genzyme Corp | Heteroarilaminosulfonamidas de 6 miembros para tratar enfermedades y afecciones mediadas por la actividad de regulador de la conductancia transmembrana de la fibrosis quistica (cftr) deficiente. |
WO2021113806A1 (fr) | 2019-12-05 | 2021-06-10 | Genzyme Corporation | Arylamides et leurs procédés d'utilisation |
WO2021113809A1 (fr) | 2019-12-05 | 2021-06-10 | Genzyme Corporation | Arylamides et leurs procédés d'utilisation |
WO2022194399A1 (fr) * | 2020-07-13 | 2022-09-22 | Idorsia Pharmaceuticals Ltd | Macrocycles en tant que modulateurs de cftr |
CN116322676A (zh) | 2020-08-13 | 2023-06-23 | 弗特克斯药品有限公司 | Cftr调节剂的结晶形式 |
WO2022076621A1 (fr) * | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique |
WO2022076624A1 (fr) * | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de conductance transmembranaire de la fibrose kystique |
US20230416275A1 (en) * | 2020-10-07 | 2023-12-28 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
CN116670143A (zh) * | 2020-10-07 | 2023-08-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控因子的调节剂 |
WO2022076618A1 (fr) * | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique |
US20230374038A1 (en) * | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
KR20230107725A (ko) * | 2020-10-07 | 2023-07-17 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막관통 전도도 조절자의 조절제 |
EP4247817A1 (fr) * | 2020-11-18 | 2023-09-27 | Vertex Pharmaceuticals Incorporated | Macrocycles contenant un cycle 1,3,4-oxadiazole destinés à être utilisés en tant que modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique |
IL303519A (en) | 2020-12-10 | 2023-08-01 | Vertex Pharma | Cystic fibrosis treatment methods |
WO2023150236A1 (fr) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Procédés de préparation et formes cristallines de (6a,12a)-17-amino-12-méthyl-6,15-bis(trifluorométhyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadéca-1(18),2,4,14,16-pentaén-6-ol |
TW202333699A (zh) | 2022-02-03 | 2023-09-01 | 美商維泰克斯製藥公司 | 囊腫纖維化之治療方法 |
WO2023154291A1 (fr) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique |
WO2023196429A1 (fr) * | 2022-04-06 | 2023-10-12 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique |
WO2023224931A1 (fr) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Méthodes de traitement de la fibrose kystique |
WO2023224924A1 (fr) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Formes solides de composés macrocycliques en tant que modulateurs de cftr et leur préparation |
WO2024054845A1 (fr) * | 2022-09-07 | 2024-03-14 | Sionna Therapeutics | Composés macrocycliques, compositions et leurs procédés d'utilisation |
WO2024054840A1 (fr) * | 2022-09-07 | 2024-03-14 | Sionna Therapeutics | Composés macrocycliques, compositions et procédés d'utilisation associés |
WO2024056791A1 (fr) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Association de modulateurs de cftr macrocycliques avec des correcteurs de cftr et/ou des potentialisateurs de cftr |
WO2024056798A1 (fr) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Modulateurs du cftr macrocycliques |
WO2024056779A1 (fr) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Forme cristalline de (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-méthoxy-1,2,4-oxadiazol-5-yl)éthyl)-6,9-diméthyl-1,5,8,11-tétraoxo-10-(2,2,2-trifluoroéthyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tétradecahydro-[1]oxa[4,7,10,14]tétraazacycloheptadécino [16,17-f]quinoléine-3-carboxamide |
CN115536493A (zh) * | 2022-10-20 | 2022-12-30 | 海门瑞一医药科技有限公司 | 一种制取3,3,3-三氟甲基-2,2-二甲基丙烷醇的简单方法 |
Family Cites Families (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2677682A (en) | 1951-08-24 | 1954-05-04 | American Cyanamid Co | Sulfonamido pteridines |
ID18983A (id) | 1996-12-04 | 1998-05-28 | Lilly Co Eli | Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia |
SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
US8933236B2 (en) | 2012-05-22 | 2015-01-13 | Xenon Pharmaceuticals Inc. | N-substituted benzamides and methods of use thereof |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
CN1612866A (zh) | 2001-11-14 | 2005-05-04 | 特瓦制药工业有限公司 | 无定形和结晶形的氯沙坦钾及其制备方法 |
CN101675928A (zh) | 2003-11-14 | 2010-03-24 | 沃泰克斯药物股份有限公司 | 可用作atp-结合弹夹转运蛋白调控剂的噻唑和噁唑 |
AU2005210474B2 (en) | 2004-01-30 | 2011-07-07 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding cassette transporters |
PL1773816T3 (pl) | 2004-06-24 | 2015-06-30 | Vertex Pharma | Modulatory transporterów posiadających kasetę wiążącą ATP |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
NZ566208A (en) | 2005-08-11 | 2010-09-30 | Vertex Pharma | 2-Thiazolamide derivatives as modulators of cystic fibrosis transmembrane conductance regulators |
WO2007053641A2 (fr) | 2005-11-01 | 2007-05-10 | Mars, Incorporated | Procyanidines de type a et inflammation |
CA2635214A1 (fr) | 2005-12-27 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Composes utiles dans les bio-essais cftr et leurs procedes |
HUE049976T2 (hu) | 2005-12-28 | 2020-11-30 | Vertex Pharma | N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói |
EP2016065B1 (fr) | 2005-12-28 | 2012-09-19 | Vertex Pharmaceuticals Incorporated | Dérivés de la 1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide et composés similaires en tant que modulateurs des transporteurs de cassettes de liaison de l'atp pour le traitement de la fibrose cystique |
US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
PL3327016T3 (pl) | 2006-04-07 | 2021-10-04 | Vertex Pharmaceuticals Incorporated | Wytwarzanie modulatorów transporterów posiadających kasetę wiążącą ATP |
EP2021797B1 (fr) | 2006-05-12 | 2011-11-23 | Vertex Pharmaceuticals, Inc. | Compositions de n-ý2,4-bis(1,1-diméthyléthyl)-5-hydroxyphényl¨-1,4-dihydro-4-oxoquinoléine-3-carboxamide |
CN101715450B (zh) | 2006-11-03 | 2013-03-13 | 沃泰克斯药物股份有限公司 | 作为cftr调控剂的氮杂吲哚衍生物 |
EP2167491A1 (fr) | 2007-06-08 | 2010-03-31 | Abbott Laboratories | Indazoles à substitution 5-hétéroaryle servant d'inhibiteurs de kinases |
US8163772B2 (en) | 2007-09-14 | 2012-04-24 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxypheny1]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
RS55559B1 (sr) | 2007-12-07 | 2017-05-31 | Vertex Pharma | Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il) benzoeve kiseline |
EA201070700A1 (ru) | 2007-12-07 | 2011-06-30 | Вертекс Фармасьютикалз Инкорпорейтед | Способы получения циклоалкилкарбоксамидопиридинбензойных кислот |
JP5523352B2 (ja) * | 2008-02-28 | 2014-06-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Cftr修飾因子としてのへテロアリール誘導体 |
NO2328618T3 (fr) | 2008-08-13 | 2018-04-28 | ||
MX2011003249A (es) | 2008-09-29 | 2011-05-19 | Vertex Pharma | Unidades de dosificacion del acido 3-(6-(1-(2,2-difluorobenzo[d][1 ,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoi co. |
BRPI0919930A2 (pt) * | 2008-10-23 | 2016-02-16 | Vertex Pharma | moduladores de regulador de condutância transmembrana de fibrose cística |
UA104876C2 (uk) | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятори atф-зв'язувальних касетних транспортерів |
SI2365972T1 (sl) | 2008-11-06 | 2015-04-30 | Vertex Pharmaceuticals Incorporated | Modulatorji prenaĺ alcev z atp-vezavno kaseto |
KR101852173B1 (ko) | 2009-03-20 | 2018-04-27 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법 |
CN102665715A (zh) | 2009-10-22 | 2012-09-12 | 沃泰克斯药物股份有限公司 | 治疗囊性纤维化和其他慢性疾病的组合物 |
EP2547658A1 (fr) | 2010-03-19 | 2013-01-23 | Vertex Pharmaceuticals Incorporated | Formes solides de n-[2,4-bis(1,1-diméthyléthyl)-5-hydroxyphényl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
CN109081804B (zh) | 2010-03-25 | 2021-12-10 | 弗特克斯药品有限公司 | 环丙烷甲酰胺的固体形式 |
NZ602838A (en) | 2010-04-07 | 2015-06-26 | Vertex Pharma | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof |
CN102933206A (zh) | 2010-04-07 | 2013-02-13 | 弗特克斯药品有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙烷甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的固体形式 |
KR101984225B1 (ko) | 2010-04-22 | 2019-05-30 | 버텍스 파마슈티칼스 인코포레이티드 | 시클로알킬카르복스아미도-인돌 화합물의 제조 방법 |
WO2011133951A1 (fr) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Compositions pharmaceutiques et leurs administrations |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
WO2012027247A2 (fr) | 2010-08-23 | 2012-03-01 | Vertex Pharmaceuticals Incorporated | Composition pharmaceutique à base de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-méthylpropan-2-yl)-1h-indol-5-yle)cyclopropane carboxamide et son administration |
NZ607494A (en) | 2010-08-27 | 2015-04-24 | Vertex Pharma | Pharmaceutical composition and administrations thereof |
HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
JP5886433B2 (ja) * | 2011-09-16 | 2016-03-16 | ノバルティス アーゲー | 嚢胞性線維症処置のためのヘテロ環式化合物 |
EP2773641B1 (fr) | 2011-10-31 | 2017-09-27 | Xenon Pharmaceuticals Inc. | Biaryléthersulfonamides et leur utilisation en tant qu'agents thérapeutiques |
ME02650B (fr) | 2011-11-08 | 2017-06-20 | Vertex Pharma | Modulateurs de transporteurs de cassette de liaison à l'atp |
UA114619C2 (uk) | 2012-01-25 | 2017-07-10 | Вертекс Фармасьютікалз Інкорпорейтед | СКЛАД 3-(6-(1-(2,2-ДИФТОРОБЕНЗО[d][1,3]ДІОКСОЛ-5-ІЛ)ЦИКЛОПРОПАНКАРБОКСАМІДО)-3-МЕТИЛПІРИДИН-2-ІЛ)БЕНЗОЙНОЇ КИСЛОТИ |
BR112014021090B1 (pt) | 2012-02-27 | 2023-01-24 | Vertex Pharmaceuticals Incorporated | Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma |
EP2838882A1 (fr) | 2012-04-20 | 2015-02-25 | Vertex Pharmaceuticals Incorporated | Formes solides de n-[2,4-bis(1,1-diméthyléthyle)-5-hydroxyphényle]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
GB201207406D0 (en) | 2012-04-27 | 2012-06-13 | Glaxo Group Ltd | Novel compounds |
CA2874851A1 (fr) | 2012-06-08 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Compositions pharmaceutiques pour le traitement des troubles a mediation par cftr |
AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
CN103571906B (zh) | 2012-07-27 | 2018-12-11 | 上海泽元海洋生物技术有限公司 | 一种利用微藻高效生产虾青素的新方法 |
NZ745659A (en) | 2012-11-02 | 2020-04-24 | Vertex Pharma | Pharmaceutical compositions for the treatment of cftr mediated diseases |
MY178621A (en) | 2012-11-19 | 2020-10-19 | Vertex Pharmaceuticals Europe Ltd | Deuterated cftr potentiators |
WO2015051043A1 (fr) | 2013-10-01 | 2015-04-09 | Amgen Inc. | Composés d'acylsulfonamide de biaryle en tant qu'inhibiteurs des canaux sodiques |
JP6963896B2 (ja) | 2013-11-12 | 2021-11-10 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Cftr媒介性疾患の処置のための医薬組成物を調製する方法 |
PT3925607T (pt) | 2014-04-15 | 2023-09-26 | Vertex Pharma | Composições farmacêuticas para o tratamento de doenças mediadas pelo regulador de condutância transmembranar da fibrose quística |
TW202140422A (zh) * | 2014-10-06 | 2021-11-01 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
KR20170063954A (ko) | 2014-10-07 | 2017-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정 |
RU2691136C2 (ru) | 2014-11-18 | 2019-06-11 | Вертекс Фармасьютикалз Инкорпорейтед | Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии |
WO2016160945A1 (fr) | 2015-03-31 | 2016-10-06 | Concert Pharmaceuticals, Inc. | Vx-661 deutéré |
MX2018003331A (es) | 2015-09-21 | 2018-08-16 | Vertex Pharmaceuticals Europe Ltd | Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados. |
EP3436432B1 (fr) | 2016-03-30 | 2021-01-27 | Genentech, Inc. | Benzamides substitués et leurs méthodes d'utilisation |
CA3019380A1 (fr) | 2016-03-31 | 2017-10-05 | Vertex Pharmaceuticals Incorporated | Modulateurs du regulateur de la conductance transmembranaire de la fibrose kystique |
KR102448404B1 (ko) | 2016-04-07 | 2022-09-27 | 프로테오스타시스 테라퓨틱스, 인크. | 규소 원자 함유 이바카프터 유사체 |
CA3016303A1 (fr) | 2016-04-26 | 2017-11-02 | Abbvie S.A.R.L. | Modulateurs de proteine regulatrice de conductance transmembranaire de la fibrose kystique |
US10138227B2 (en) | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
US10899751B2 (en) | 2016-06-21 | 2021-01-26 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
CN109803962B (zh) * | 2016-09-30 | 2022-04-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物 |
US9981910B2 (en) | 2016-10-07 | 2018-05-29 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
US10399940B2 (en) | 2016-10-07 | 2019-09-03 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
US20190256474A1 (en) | 2016-10-26 | 2019-08-22 | Proteostasis Therapeutics, Inc. | N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis |
CA3041676A1 (fr) | 2016-10-26 | 2018-05-03 | Daniel Parks | Composes de pyridazine, compositions et methodes permettant de moduler cftr |
AU2017348183A1 (en) | 2016-10-26 | 2019-05-16 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for modulating CFTR |
WO2018080591A1 (fr) | 2016-10-27 | 2018-05-03 | Vertex Pharmaceuticals (Europe) Limited | Procédés de traitement avec des potentialisateurs cftr deutérés |
EP3541390B1 (fr) | 2016-11-18 | 2024-05-01 | Cystic Fibrosis Foundation | Pyrrolopyrimidines utilisées comme potentialisateurs de cftr |
HUE052205T2 (hu) | 2016-12-09 | 2021-04-28 | Vertex Pharma | Cisztás fibrózis transzmembrán vezetõképesség szabályzó modulátora, gyógyszerészeti készítmények, kezelési eljárások és eljárás a modulátor elõállítására |
EP3554506B1 (fr) | 2016-12-16 | 2021-04-28 | Cystic Fibrosis Foundation | Dérivés d'hétéroaryle bycyclique en tant que potentialisateurs du cftr |
WO2018116185A1 (fr) | 2016-12-20 | 2018-06-28 | AbbVie S.à.r.l. | Modulateurs cftr deutérés et procédés d'utilisation |
EP3565815B1 (fr) | 2017-01-07 | 2024-03-13 | Fochon Pharmaceuticals, Ltd. | Composés en tant qu'agents induisant l'apoptose sélective de bcl-2 |
TW201831471A (zh) | 2017-02-24 | 2018-09-01 | 盧森堡商艾伯維公司 | 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法 |
US20180280349A1 (en) | 2017-03-28 | 2018-10-04 | Vertex Pharmaceuticals Incorporated | Methods of treating cystic fibrosis in patients with residual function mutations |
MA48994A (fr) | 2017-03-30 | 2020-02-05 | Hoffmann La Roche | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 |
EP3615528B1 (fr) | 2017-04-28 | 2022-02-16 | Proteostasis Therapeutics, Inc. | Dérivés 4-sulfonylaminocarbonylquinoline pour augmenter l'activité cftr |
US11253509B2 (en) | 2017-06-08 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2019010092A1 (fr) | 2017-07-01 | 2019-01-10 | Vertex Pharmaceuticals Incorporated | Compositions et méthodes de traitement de la fibrose kystique |
TW201920081A (zh) | 2017-07-11 | 2019-06-01 | 美商維泰克斯製藥公司 | 作為鈉通道調節劑的羧醯胺 |
BR112020000941A2 (pt) | 2017-07-17 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
WO2019018353A1 (fr) | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | Méthodes de traitement de la fibrose kystique |
EP3662079A4 (fr) | 2017-07-31 | 2021-04-14 | Technion Research & Development Foundation Limited | Procédés de détection d'adn modifié et non modifié |
US11434201B2 (en) | 2017-08-02 | 2022-09-06 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
US10988454B2 (en) | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
CA3078230A1 (fr) | 2017-10-06 | 2019-04-11 | Proteostasis Therapeutics, Inc. | Composes, compositions et methodes pour augmenter l'activite de cftr |
WO2019079760A1 (fr) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Formes cristallines et compositions de modulateurs de cftr |
WO2019113089A1 (fr) | 2017-12-04 | 2019-06-13 | Vertex Pharmaceuticals Incorporated | Compositions pour le traitement de la mucoviscidose |
WO2019113476A2 (fr) | 2017-12-08 | 2019-06-13 | Vertex Pharmaceuticals Incorporated | Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose |
TWI810243B (zh) * | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
MX2020008268A (es) | 2018-02-15 | 2020-09-21 | Vertex Pharma | Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quistica, composiciones farmaceuticas de estos, su uso en el tratamiento de la fibrosis quistica y procesos para elaborarlos. |
WO2019191620A1 (fr) | 2018-03-30 | 2019-10-03 | Vertex Pharmaceuticals Incorporated | Formes cristallines de modulateurs de cftr |
US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
MA54227B1 (fr) | 2018-11-14 | 2023-03-31 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
CA3119656A1 (fr) | 2018-12-21 | 2020-06-25 | Novartis Ag | Composes macrocycliques et leur utilisation dans le traitement de maladies |
US20220127247A1 (en) | 2019-02-06 | 2022-04-28 | Novartis Ag | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease |
WO2020191227A1 (fr) | 2019-03-20 | 2020-09-24 | Cornell University | Méthodes de régulation de processus biologiques à médiation par la prostaglandine |
TW202102482A (zh) | 2019-04-03 | 2021-01-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
WO2020214921A1 (fr) | 2019-04-17 | 2020-10-22 | Vertex Pharmaceuticals Incorporated | Formes solides de modulateurs de cftr |
WO2020242935A1 (fr) | 2019-05-29 | 2020-12-03 | Vertex Pharmaceuticals Incorporated | Méthodes de traitement de la mucoviscidose |
CN114585628B (zh) | 2019-08-14 | 2024-03-26 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节因子的调节剂 |
TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
BR112022002605A2 (pt) | 2019-08-14 | 2022-05-03 | Vertex Pharma | Formas cristalinas de moduladores de cftr |
MX2022005810A (es) | 2019-11-12 | 2022-06-08 | Genzyme Corp | Heteroarilaminosulfonamidas de 6 miembros para tratar enfermedades y afecciones mediadas por la actividad de regulador de la conductancia transmembrana de la fibrosis quistica (cftr) deficiente. |
AU2020384279A1 (en) | 2019-11-12 | 2022-05-26 | Genzyme Corporation | 5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient CFTR activity |
CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
CN116322676A (zh) | 2020-08-13 | 2023-06-23 | 弗特克斯药品有限公司 | Cftr调节剂的结晶形式 |
-
2019
- 2019-02-14 MX MX2020008268A patent/MX2020008268A/es unknown
- 2019-02-14 UA UAA202005844A patent/UA126304C2/uk unknown
- 2019-02-14 ES ES19707648T patent/ES2939775T3/es active Active
- 2019-02-14 JP JP2020543326A patent/JP7214743B2/ja active Active
- 2019-02-14 LT LTEPPCT/US2019/018042T patent/LT3752510T/lt unknown
- 2019-02-14 MA MA51828A patent/MA51828B1/fr unknown
- 2019-02-14 WO PCT/US2019/018042 patent/WO2019161078A1/fr active Application Filing
- 2019-02-14 RS RS20230079A patent/RS64018B1/sr unknown
- 2019-02-14 BR BR112020015509-8A patent/BR112020015509A2/pt unknown
- 2019-02-14 MD MDE20201268T patent/MD3752510T2/ro unknown
- 2019-02-14 SI SI201930446T patent/SI3752510T1/sl unknown
- 2019-02-14 CN CN201980025942.6A patent/CN112004817B/zh active Active
- 2019-02-14 PL PL19707648.2T patent/PL3752510T3/pl unknown
- 2019-02-14 AU AU2019222758A patent/AU2019222758B2/en active Active
- 2019-02-14 AR ARP190100372A patent/AR114254A1/es unknown
- 2019-02-14 JO JOP/2020/0178A patent/JOP20200178A1/ar unknown
- 2019-02-14 SG SG11202006614VA patent/SG11202006614VA/en unknown
- 2019-02-14 HR HRP20230030TT patent/HRP20230030T1/hr unknown
- 2019-02-14 CR CR20200403A patent/CR20200403A/es unknown
- 2019-02-14 FI FIEP19707648.2T patent/FI3752510T3/fi active
- 2019-02-14 US US16/276,350 patent/US11066417B2/en active Active
- 2019-02-14 EA EA202091930A patent/EA202091930A1/ru unknown
- 2019-02-14 PE PE2020001222A patent/PE20210454A1/es unknown
- 2019-02-14 EP EP19707648.2A patent/EP3752510B1/fr active Active
- 2019-02-14 KR KR1020207026102A patent/KR102482271B1/ko active IP Right Grant
- 2019-02-14 GE GEAP201915439A patent/GEP20237571B/en unknown
- 2019-02-14 EP EP22209444.3A patent/EP4198037A1/fr active Pending
- 2019-02-14 IL IL294042A patent/IL294042A/en unknown
- 2019-02-14 CN CN202310999824.3A patent/CN117285547A/zh active Pending
- 2019-02-14 DK DK19707648.2T patent/DK3752510T3/da active
- 2019-02-14 CA CA3088577A patent/CA3088577A1/fr active Pending
- 2019-02-14 HU HUE19707648A patent/HUE061046T2/hu unknown
- 2019-02-14 IL IL276662A patent/IL276662B/en unknown
- 2019-02-14 PT PT197076482T patent/PT3752510T/pt unknown
- 2019-02-15 UY UY38093A patent/UY38093A/es unknown
- 2019-02-15 TW TW111138279A patent/TWI828358B/zh active
- 2019-02-15 TW TW108105209A patent/TWI780304B/zh active
-
2020
- 2020-07-15 ZA ZA2020/04357A patent/ZA202004357B/en unknown
- 2020-08-07 CL CL2020002055A patent/CL2020002055A1/es unknown
- 2020-09-04 EC ECSENADI202053845A patent/ECSP20053845A/es unknown
-
2021
- 2021-05-18 US US17/323,267 patent/US11866450B2/en active Active
-
2022
- 2022-06-23 JP JP2022100979A patent/JP2022126802A/ja not_active Withdrawn
- 2022-09-15 AU AU2022231721A patent/AU2022231721A1/en active Pending
-
2023
- 2023-01-27 DO DO2023000016A patent/DOP2023000016A/es unknown
-
2024
- 2024-02-05 JP JP2024015975A patent/JP2024050811A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA51828B1 (fr) | Macrocycles utilisés en tant que modulateurs du régulateur de la conductance transmembranaire de fibrose kystique, compositions pharmaceutiques de ceux-ci, leur utilisation dans le traitement de la fibrose kystique et procédé de fabrication associé | |
MA46357B1 (fr) | Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur | |
MA49235B1 (fr) | Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur | |
MA50240B1 (fr) | Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation | |
MA55533B1 (fr) | Agents de modulation de régulateur de conductance transmembranaire de fibrose kystique | |
MA45222A (fr) | Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
MA39995B1 (fr) | Composés destinés à traiter l'amyotrophie spinale | |
MA43639B1 (fr) | Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
NO20062704L (no) | Azabicykliske heterocykler som cannabinoide reseptormodulatorer | |
MA47301B1 (fr) | Inhibiteurs sélectifs de jak1 | |
MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
MA41337A (fr) | Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3 | |
MA42769B1 (fr) | Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 | |
MA39926B1 (fr) | Dérivés de dihétérocycle liés à cycloalkyle | |
MA51534B1 (fr) | Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation | |
CR20190211A (es) | Modulador del regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador | |
MA50457B1 (fr) | Dérivés de pyridine carbonyle et leurs utilisations thérapeutiques en tant qu'inhibiteurs de trpc6 | |
UY39604A (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso | |
MA56098B1 (fr) | Immunomodulateurs hétérocycliques autant qu'inhibiteurs de pdl1 | |
MA51146B1 (fr) | Composés hétérocycliques bicycliques substitués utilisés en tant qu'inhibiteurs de prmt5 | |
EA201990850A1 (ru) | Модулятор муковисцидозного трансмембранного регулятора проводимости, фармацевтические композиции, способы лечения и способы получения модулятора | |
MA39153A1 (fr) | Nouveaux composés hétérocycliques |